To the editor,

Bipolar disorder (BD) is a chronic recurring mood disorder with a lifetime prevalence of 1.06%.\[[@ref1]\] BD is associated with comorbid substance use, medical illnesses, suicidal behaviors, and biorhythm irregularities, leading to increased morbidity and mortality.\[[@ref2][@ref3]\]

Suicidality is one of the preventable causes of mortality in BD. The prevalence rates of suicide attempts (25--50%) and suicidal deaths (8--19%) are higher among BD-I patients than the general population.\[[@ref4]\] There are various biopsychosocial risk factors for suicidality in BD.\[[@ref5]\]

Neurotrophins such as brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) are actively researched as biomarkers in BD. BDNF is biologically activated by MMP-9, leading to effective neuronal growth and synaptic plasticity.\[[@ref6]\] Studies reveal that suicidality and BD are independently associated with raised MMP-9 levels.\[[@ref7][@ref8]\]

The present study aimed to evaluate the relationship between MMP-9 levels and lifetime history of suicide attempt in remitted BD-I patients.

MATERIALS AND METHODS {#sec1-2}
=====================

The study was cross-sectional in design, and the participants were recruited by purposive sampling in a tertiary-cum-teaching hospital in southern India. Patients with BD-I (*n* = 150) were enrolled into the parent study, which analyzed the course and outcome of BD-I among Indian patients.\[[@ref9]\] A subset of patients (*n* = 60) from the parent study was studied for neurotrophic markers (MMP-9) and cognitive functions in another unpublished research. Those patients with data on illness course, suicidality, and neurotrophic markers were included in the present pilot study.

Patients aged 18--65 years, with BD-I diagnosis as per Structured Clinical Interview for DSM-IV-TR Axis-I Disorders (SCID-I),\[[@ref10]\] with illness duration of minimum 3 years, and currently in clinical remission as defined by Hamilton Depression Rating Scale (HDRS) score \<8 and Young Mania Rating Scale (YMRS) score \<7 were included.\[[@ref11][@ref12]\] Patients with active substance use in the past 12 weeks or having medical/neurological illnesses were excluded.

Sociodemographic data were collected using a semi-structured proforma. The illness course was systematically charted in the National Institute of Mental Health -- Life Chart Methodology (Retrospective) chart.\[[@ref13]\] The severity of lifetime suicide behavior was assessed using the Columbia Suicide Severity Rating Scale (C-SSRS).\[[@ref14]\] Serum MMP-9 levels were assessed using the enzyme-linked immunoassay method. Informed consent was obtained from all the participants, and the Institute Ethics Committee approved the study protocol.\[[@ref9]\]

Non-parametric tests were chosen for this sample due to the non-uniform distribution of MMP-9 values. After appropriate descriptive analyses, Mann--Whitney U test was used for comparison for dichotomous variables and Kendall\'s τ *b* was used for non-parametric correlation with the continuous data. No sensitivity analysis was performed. Statistical analyses were conducted using SPSS 19 (IBM Corp, Armonk, NY), and *P* \< 0.05 was considered significant.

RESULTS {#sec1-3}
=======

Remitted BD-I patients (*n* = 25) were recruited. The mean age was 34.0 years (range 22--56 years), with 60% being females. The participants were mainly home-makers, and were educated above 10^th^ grade. A major proportion (92%) belonged to the lower socioeconomic status. The mean duration of BD was 12.1 years (range 3--24 years), with a mean of 5 episodes (range 2--13). Eleven participants (44%) had unipolar mania. The lifetime history of a suicide attempt was noted in 20% (*n* = 5) of the participants.

In the present study, only 6 out of 25 subjects (24%) had MMP-9 levels within the standard normal range (11.4-59.4 ng/ml), with the remainder having less than normal levels. The mean MMP-9 level in the entire sample was 9.09 ± 11.58 ng/ml. The levels of MMP-9 were higher in patients with a lifetime history of a suicide attempt when compared to those without (20.25 ± 169.49 ng/ml vs. 6.29 ± 8.24 ng/ml, Mann--Whitney U = 14.000, *P* = 0.014). MMP-9 levels negatively correlated with the age of the participants (Kendall\'s τ *b* = -0.264, *P* = 0.068) and the duration of BD (Kendall\'s τ *b* = -0.279, *P* = 0.057), with a trend toward significance \[[Table 1](#T1){ref-type="table"}\].

###### 

Relationship of MMP-9 with clinical variables

  Variable                             Relationship with MMP-9 levels^†^ Test statistic (*P*)
  ------------------------------------ --------------------------------------------------------
  Age^‡^                               -0.264 (0.068)
  Gender^§^                            75.0 (1.000)
  Duration of BD-I^‡^                  -0.279 (0.057)
  Number of episodes^‡^                0.042 (0.776)
  Only manic polarity^‡^               74.0 (0.893)
  Past history of suicide attempt^§^   14.0 (0.012)\*

^†^Relationship assessed using Kendall t b (for continuous data^‡^) or Mann Whitney U (dichotomous data^§^), \**P*\>0.05. BD-Bipolar Disorder-type I, MMP-Matrix Metalloproteinase

DISCUSSION {#sec1-4}
==========

The prevalence rate of suicide attempts in the study population was comparable to those observed in a previously reported study\[[@ref15]\] A preponderance of T-allele versus C-allele of 1562C/T of the MMP-9 gene was found in BD patients compared to control subjects, leading to pro-inflammatory changes.\[[@ref16][@ref17]\] Considering the neuroinflammatory hypothesis of BD, increased MMP-9 levels could be considered a marker of an inflammatory state.

In the current study, elevated MMP-9 levels were associated with a lifetime history of suicide attempt in BD, suggesting the role of a state marker for suicidality.\[[@ref9]\] However, the evidence remains inconclusive on the nature of the association of MMP-9 with the illness phase (acute/remission). While some studies reported elevated MMP-9 during the remission phase,\[[@ref17]\] some other studies have revealed increased MMP-9 during both acute and remission phases of depression.\[[@ref18][@ref19]\] Variation of MMP-9 levels with age, as noted in previous studies, could not be replicated in the present study, probably due to the low sample size.\[[@ref18]\]

Despite being one of the first Indian studies exploring the role of MMP-9 in suicidality, the study has the following limitations:

The present study is a pilot study with a small sample size, and a minuscule proportion with the variable of interest (i.e., suicidal attempts in the past) would have influenced the negative association between MMP-9 and clinical characteristicsLack of a control group precludes an interpretation of MMP-9 levels as a marker of suicidality in BD-IThe retrospective study design had inherent recall bias.

Nevertheless, the present study emphasizes the need to assess newer markers such as MMP-9 in suicidality observed in BD. Future studies with a large sample size and a control group will help elucidate the role of biomarkers in suicidality associated with BD.
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